RESUMO
Stroke is a major cause of neurological disability across all countries in the world. Functional recovery after stroke is limited because of neuronal death and degeneration. Although early reperfusion therapy may improve outcome, thrombolysis does not reverse ischaemic neuronal death and carries the risk of cerebral haemorrhage. Early trials of stem cell therapy in promoting functional recovery after completed stroke remain inconclusive. Based on experimental data, we propose human umbilical cord blood transfusion as a possible therapy for ischaemic cerebral stroke to aid functional recovery.
Assuntos
Transfusão de Sangue/métodos , Isquemia Encefálica/terapia , Sangue Fetal/metabolismo , Placenta/metabolismo , Acidente Vascular Cerebral/terapia , Doença Aguda , Encefalopatias/patologia , Ensaios Clínicos como Assunto , Humanos , Modelos Teóricos , Neurônios/metabolismo , Risco , Células-Tronco/citologia , Terapia Trombolítica , Fatores de TempoRESUMO
WideCells Group PLC (Manchester, UK) is a global stem cell services company with the aim of leading a transformation in cord blood banking and stem cell treatment. There are three key divisions: WideCells, WideAcademy and CellPlan. WideCells provides contract, collaborative and in-house research, and stem cell processing and storage facilities for a wide range of human tissues. WideAcademy, the education and training branch of the WideCells Group, aims to become the thought leader in stem cell technology, influencing and informing the next generation of healthcare professionals working in stem cell technology. CellPlan is a first-of-its-kind medical insurance plan to make stem cell treatment accessible and affordable by providing access to renowned specialists and hospitals globally with financial cover for cord blood transplantation and for participation in clinical trials using cord blood.
Assuntos
Pesquisa com Células-Tronco , Bancos de Sangue , Sangue Fetal/metabolismo , Humanos , SeguroRESUMO
International private umbilical cord blood banking has expanded rapidly in recent years since the first cord blood transplant which was 20 years ago. Private companies offer parents the opportunity to store umbilical cord blood for the possible future use by their child or other family members. The private cord blood industry has been criticised by a number of professional bodies including the EU Ethics Committee, the Royal College of Obstetrics and Gynaecology, the Royal College of Midwives and the US College of Paediatrics. This review presents the arguments from the opponents of private cord blood banking, and then makes the case for private cord banking based on the latest scientific and clinical evidence.